A randomized clinical trial compared efficacy and toxicity of standard all-trans-retinoic acid ( ATRA ) plus chemotherapy versus ATRA plus arsenic trioxide in patients with newly diagnosed , low - or intermediate-risk acute promyelocytic leukemia ( APL ) .